Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
12/2003
12/18/2003WO2003103595A2 Androgen receptor coregulators
12/18/2003WO2003103592A2 Covalent conjugates between artemisinin-related endoperoxides and iron-carrying proteins and methods of use
12/18/2003WO2003103589A2 Use of il-21 in cancer and other therapeutic applications
12/18/2003WO2003103588A2 Methods of using artemisinin-like compounds to prevent or delay the appearance of cancer
12/18/2003WO2003103581A2 Compositions and methods for liver growth and liver protection
12/18/2003WO2003103577A2 Novel recombinant anticoagulant proteins
12/18/2003WO2003103573A2 Methods for treating a neurological disorder by peripheral administration of a trophic factor
12/18/2003WO2003103572A2 Modified glucagon-like peptide-1 analogs
12/18/2003WO2003103478A2 Methods for using adamts-12, an integrin and metalloprotease with thrombospondin motifs
12/18/2003WO2003103475A2 Prevention and reduction of blood loss
12/18/2003WO2003086323A3 Compositions and methods for immunomodulation
12/18/2003WO2003084995A3 Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between cd28 and the superantigen and uses thereof
12/18/2003WO2003082302A3 Bioadhesive directed somatic cell therapy
12/18/2003WO2003082019A3 Peptides with anti-hypertensive properties
12/18/2003WO2003079991A3 Method for administration of growth hormone via pulmonary delivery
12/18/2003WO2003074558A3 Spheron components useful in determining compounds capable of treating symptoms of alzheimer's disease, and treatments and animal models produced therefrom
12/18/2003WO2003074068A3 Use of soluble fgl2 as an immunosuppressant
12/18/2003WO2003072606A3 Galectin-8and functional derivatives as binding agents for cd44 glycoproteins and methods of use
12/18/2003WO2003072599A3 Novel chemokine binding peptides capable of modulating the biological activity of chemokines
12/18/2003WO2003070018A3 Food products comprising soy protein
12/18/2003WO2003068930A3 Pseudomonas avr and hop proteins, their encoding nucleic acids, and use thereof
12/18/2003WO2003061704A3 Combination therapy for the treatment of bacterial infections
12/18/2003WO2003059329A3 Polytartrate composition
12/18/2003WO2003057911A3 Single nucleotide polymorphisms predicting cardiovascular disease and medication efficacy
12/18/2003WO2003057849A3 Telomere-encoding synthetic dna nanocircles, and their use for the elongation of telomere repeats
12/18/2003WO2003057244A3 Use of amylin agonists to modulate triglycerides
12/18/2003WO2003051917A3 Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
12/18/2003WO2003051401A3 Stabilised mrna tumour vaccine
12/18/2003WO2003051281A3 Composition and method to treat viral bacterial and parasitic infections and infestations
12/18/2003WO2003050108A8 Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
12/18/2003WO2003046179A3 G-protein coupled receptor lustr2 and uses thereof
12/18/2003WO2003045330A3 Materials and methods for making improved micelle compositions
12/18/2003WO2003041657A3 Antisense modulation of vitamin d nuclear receptor expression
12/18/2003WO2003040336A3 Stem and progenitor cell capture for tissue regeneration
12/18/2003WO2003040309A3 Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
12/18/2003WO2003039677A3 Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
12/18/2003WO2003039444B1 Topical use of cytokines and/or chemokines for the treatment of viral or mykotic skin diseases or tumoral diseases
12/18/2003WO2003037164A3 Methods and compositions for the diagnosis and treatment of hematological disorders using 2777
12/18/2003WO2003032926A3 Compositions and methods for reversal of drug resistance
12/18/2003WO2003031606A3 Crystal structure of an aurora kinase catalytic domain, and use thereof
12/18/2003WO2003030885A3 Modulation of the adventitial tool-like receptor
12/18/2003WO2003029437A3 Secreted proteins
12/18/2003WO2003029414A3 INTRODUCTION OF THE WLDs GENE FOR PREVENTION OF AXONAL DEGENERATION IN NEUROLOGICAL DISEASES
12/18/2003WO2003027265A3 Composition and methods for enhancing oligonucleotide-directed nucleic acid sequence alteration
12/18/2003WO2003027244A3 Antisense oligonucleotides and methods to induce tumor cell death
12/18/2003WO2003026693A3 Inhibitors of costimulation by 0x40 and their use against infectious diseases
12/18/2003WO2003022303A3 Use of hcg and lh in controlled ovarian hyperstimulation
12/18/2003WO2003022302A3 USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION
12/18/2003WO2003014342A3 Identification of a dna variant associated with adult type hypolactasia
12/18/2003WO2003013536A3 Methods for treatment of cancer using irinotecan based on ugt1a1
12/18/2003WO2003006619A3 Calcineurin modulators
12/18/2003WO2003002068A3 Diagnosis and treatment of cancer
12/18/2003WO2003000916A3 Telomerase expression repressor proteins and methods of using the same
12/18/2003WO2003000864A8 Nucleic acid-associated proteins
12/18/2003WO2003000725A3 Regulation of human lipoate-protein ligase b-like enzyme
12/18/2003WO2002101049A3 Interleukin-18 mutants, their production and use
12/18/2003WO2002099035A3 Chimeric alphavirus replicon particles
12/18/2003WO2002092788A3 Cytotoxic peptides and peptidomimetics based thereon, and methods for use thereof
12/18/2003WO2002092781A3 Peptide compounds for counteracting reactive oxygen species and free radicals
12/18/2003WO2002090543A3 Regulation of human phosphatidic acid phosphatase type 2c-like protein
12/18/2003WO2002089731A3 Agents for treatment of hcv and methods of use
12/18/2003WO2002087417A3 Alleviation of the memory deficits and memory components of psychiatric dysfunctions by altering atypical pkm activity
12/18/2003WO2002083030A3 Bifunctional energy-reversible acyl-compositions
12/18/2003WO2002081627A3 Methods of screening and using inhibitors of angiogenesis
12/18/2003WO2002079474A3 Human b7 polypeptides
12/18/2003WO2002078618A3 Methods of modulating surfactant production
12/18/2003WO2002078599A3 CD8α + LYMPHOID DENDRITIC CELL DIFFERENTIATED FROM HUMAN HEMATOPOIETIC STEM CELL AND A METHOD FOR DIFFERENTIATION
12/18/2003WO2002070660A3 Proteins and nucleic acids encoding same
12/18/2003WO2002068626A3 Novel human ion channel-related proteins and polynucleotides encoding the same
12/18/2003WO2002066668A3 Method for producing proteins by fermentation of microorganisms from the thermus family, the protein mixture thus obtained and cosmetic compositions containing same
12/18/2003WO2002066504A3 Protein-protein interactions in saccharomyces cerevisiae
12/18/2003WO2002064740A3 Cone snail peptides
12/18/2003WO2002062955A3 Dendritic enriched secreted lymphocyte activation molecule
12/18/2003WO2002058724A3 Use of lp82 to treat body weight disorders
12/18/2003WO2002058723A3 Chemokines as adjuvants of immune response
12/18/2003WO2002057440A3 Screens and assays for agents useful in controlling parasitic nematodes
12/18/2003WO2002047716A3 Chronic treatment regimen using glucagon-like insulinotropic peptides
12/18/2003WO2002030257A9 Normalization of defective t cell responsiveness through manipulation of thymic regeneration
12/18/2003WO2002017878A8 Lung surfactant compositions with dynamic swelling behaviour
12/18/2003WO2002007678A3 Mu-conopeptides
12/18/2003WO2000040718A3 MUTANTS OF GNRPs AND VECTORS SUITABLE FOR THEIR EXPRESSION
12/18/2003US20030232986 Inhibitors of caspases
12/18/2003US20030232977 Antisense modulation of splicing factor R/S-rich 10 expression
12/18/2003US20030232976 Comprises nucleotide sequences coding polypeptides for diagnosis, prevention and treatment of meningitis, inflammations, bacterial and pneumonia infections
12/18/2003US20030232975 Comprises nucleotide sequences coding polypeptides for diagnosing, preventing and treating cancer
12/18/2003US20030232971 Tumour necrosis factor binding ligands
12/18/2003US20030232970 Monoclonal antibody for treatment of tumor disorders; antitumor agents
12/18/2003US20030232966 For treatment of encephalomyelitis, leukodystrophy, adrenoleukodystrophy, migraines, epilepsy, Alzheimer's/Parkinson's diseases, and neuron diseases
12/18/2003US20030232873 Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR)
12/18/2003US20030232851 Viral treatment
12/18/2003US20030232806 Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them
12/18/2003US20030232793 Comprising hyperglycemia, insulin dependent diabetes mellitus, impaired glucose tolerance, hyperinsulinemia, insulin insensitivity, diabetes related diseases
12/18/2003US20030232788 Inhibitors of interleukin-1 beta converting enzyme and related proteases
12/18/2003US20030232780 Composition comprising an immunomodulatory molecule, which molecule comprises an antigen conjugated to an polynucleotide that contains at least one immunostimulatory nucleotide sequence; for modulating an immune response in vertebrates
12/18/2003US20030232778 Oligonucleotides, specifically hybridizable with nucleic acids encoding extracellular-signal-regulated kinase-6; can be used to modulate the expression of extracellular-signal-regulated kinase-6
12/18/2003US20030232777 An oligonucleotides or polynucleotides targeted to hybridization with the nucleic acids, gene expression inhibition, treating angiogenic diseases, metabolic disease, neurodegenerative disease, cancer, inflammation; gene therapy
12/18/2003US20030232775 Antisense modulation of phosphatidylinositol-4-phosphate 5-kinase, type II beta expression
12/18/2003US20030232774 Antisense modulation of profilin 1 expression
12/18/2003US20030232773 An oligonucleotides or polynucleotides targeted to hybridization, death-associated protein kinase-inducing protein kinase 1, treating Alzheimer's disease, cancer, neurodegenerative disease, inflammation; gene therapy
12/18/2003US20030232772 Antisense modulation of extracellular-signal-regulated kinase-6 expression
1 ... 1710 1711 1712 1713 1714 1715 1716 1717 1718 1719 1720 1721 1722 1723 1724 1725 1726 1727 1728 1729 1730 ... 3163